Depression, hallucinations, and delusions are frequent complications of Alzheimer's disease (AD); therefore, AD may provide a model for studying the pathophysiology of these symptoms. Two recent finding support the utility of this approach: depression in AD is genetically related to depression occurring in major affective illness; and, in our preliminary studies, cases of AD with depression have a greater loss of nonadrenergic neurons of the locus coeruleus than cases of AD without depression, In Project 5, we propose to investigate the relationships between psychiatric symptoms in AD and the pathology in brainstem monoaminergic circuits. Cases of AD with or without depression and cases with or without psychosis will be prospectively matched for age of onset, duration of illness, and the score of the last Mini-Mental Status Examination. First, in depressed vs. nondepressed cases of AD, we will count noradrenergic neurons of locus coeruleus and serotoninergic neurons of nucleus raphe dorsalis and nucleus centralis superior. We predict that cases of AD with depression will have greater loss of neurons in specific regions of these nuclei than cases of AD without depression. Second, we will count dopaminergic neurons in several defined subnuclei within the ventral tegmental area in cases of AD with or without psychosis. We hypothesize that individuals with psychosis will have greater losses of these dopaminergic neurons than individuals without psychosis. Third, using transmitter-marker autoradiography and neurochemical techniques, we will correlate abnormalities in these brainstem nuclei with decrements in monoaminergic markers in target fields within the forebrain. By clarifying the relationships between psychiatric symptoms in AD and abnormalities of defined monoaminergic neurons, these studies may provide new insights into the pathophysiology of psychiatric disorders in AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005146-09
Application #
3802571
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Seddighi, Sahba; Varma, Vijay R; An, Yang et al. (2018) SPARCL1 Accelerates Symptom Onset in Alzheimer's Disease and Influences Brain Structure and Function During Aging. J Alzheimers Dis 61:401-414
Fredericks, Carolyn A; Sturm, Virginia E; Brown, Jesse A et al. (2018) Early affective changes and increased connectivity in preclinical Alzheimer's disease. Alzheimers Dement (Amst) 10:471-479
Holingue, Calliope; Wennberg, Alexandra; Berger, Slava et al. (2018) Disturbed sleep and diabetes: A potential nexus of dementia risk. Metabolism 84:85-93
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
van Bergen, Jiri M G; Li, Xu; Quevenco, Frances C et al. (2018) Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old. Neurobiol Aging 64:68-75
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Kim, Sangjune; Yun, Seung Pil; Lee, Saebom et al. (2018) GBA1 deficiency negatively affects physiological ?-synuclein tetramers and related multimers. Proc Natl Acad Sci U S A 115:798-803
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Hohman, Timothy J; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurol 75:989-998

Showing the most recent 10 out of 830 publications